Hosted on MSN

2 beaten-down stocks that still aren't worth buying

Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy. 10 ...
The Motley Fool

2 Beaten-Down Stocks That Still Aren't Worth Buying

Recursion Pharmaceuticals is a drugmaker that relies on artificial intelligence (AI) to go from discovery to the market. The company is betting that its approach can succeed where other breakthroughs ...